Anzeige
Mehr »
Login
Mittwoch, 29.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Energiekrise als Chance: Mit dieser Aktie starten Sie ins Börsenjahr 2025 durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DM94 | ISIN: CA4969024047 | Ticker-Symbol: KIN2
Tradegate
28.01.25
20:52 Uhr
10,410 Euro
-0,015
-0,14 %
1-Jahres-Chart
KINROSS GOLD CORPORATION Chart 1 Jahr
5-Tage-Chart
KINROSS GOLD CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
10,40010,48028.01.
0,0000,00028.01.
GlobeNewswire (Europe)
159 Leser
Artikel bewerten:
(1)

Puma Exploration Inc.: Puma Closes the Option Agreement and $1M Private Placement with Kinross Gold

Finanznachrichten News

RIMOUSKI, Quebec, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the "Company" or "Puma") is pleased to announce that it has closed its Option Agreement for the Williams Brook, Portage and Jonpol properties (collectively, the "Williams Brook Project") announced on October 24, 2024 including a non-brokered private placement for $1,011,473.47 with Kinross Gold Corporation (TSX: K, NYSE: KGC) ("Kinross").

In connection with the Option Agreement, Kinross subscribed to 16,857,891 common shares of the Company at a price of $0.06 ("the Offering"). Kinross now holds approximately 9.9% of Puma's issued and outstanding shares. Puma and Kinross have also executed an investor rights agreement (the "IRA"), pursuant to which, among other things, Kinross will be granted the right to participate in future equity financings in order to maintain its ownership percentage in the Company or acquire up to 19.9% of the total of common shares of the Company issued and outstanding after issuance of new securities.

The Private Placement was negotiated at arms' length with no associated finder's fees. All securities issued under the Offering will have a statutory hold period of four months and one day. The net proceeds of the Offering will be used by the Company to explore its other projects and for general corporate and working capital purposes. The Company expects to release news regarding its short to medium-term strategy for its other 100% held properties in the coming weeks.

The option Agreement and the Private Placement received conditional approval from the TSXV.

About Puma's Assets in New Brunswick

Puma has accumulated an impressive portfolio of prospective gold landholdings in Northern New Brunswick - the Williams Brook, JonPol, Portage, TIMM and Jacquet River properties. They are all located near the Rocky Brook Millstream Fault ("RBMF"), a major regional structure formed during the Appalachian Orogeny and a significant control for gold deposition in the region. Puma's work to date has focused on the Williams Brook property, but prospecting and surface exploration work on the other properties have confirmed their potential for significant gold mineralization. Puma retains its 100% interest in the TIMM and Jacquet River properties and will continue to advance their development.

The Company is committed to its DEAR business model of Discovery, Exploration, Acquisition and Royalties to generate maximum value for shareholders with low share dilution.

About Puma Exploration

Puma Exploration is a Canadian-based mineral exploration company with precious metals projects in New Brunswick, near Canada's Famous Bathurst Mining Camp. Puma has a long history in Northern New Brunswick, having worked on regional projects for over 15 years. Puma's successful exploration methodology, which combines old prospecting methods with detailed trenching and up-to-date technology such as Artificial Intelligence, has been instrumental in facilitating an understanding of the region's geology and associated mineralized systems. Armed with geophysical surveys, geochemical data and consultants' expertise, Puma has developed a perfect low-cost exploration tool to discover gold at shallow depths and maximize drilling results.

Connect with us on Facebook / X/ LinkedIn.
Visit www.explorationpuma.com for more information or contact:

Marcel Robillard, President and CEO.
(418) 750-8510; president@explorationpuma.com

Mia Boiridy, Head of Investor Relations and Corporate Development.
(250) 575-3305; mboiridy@explorationpuma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This press release may contain forward-looking statements. Such forward-looking statements involve several known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of Puma to be materially different from actual future results and achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, except as required by law. Puma undertakes no obligation to publicly update or revise any forward-looking statements. The quarterly and annual reports and the documents submitted to the securities administration describe these risks and uncertainties.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.